Abstract | OBJECTIVE: METHODS: We performed a retrospective study of 342 patients with CHB who underwent interferon treatment for >12 weeks. Patients with thyroid dysfunction before or during treatment were defined as the thyroid dysfunction group (n = 141) and those with normal thyroid function were defined as the normal thyroid function group (n = 201). The prevalences of hepatitis B virus (HBV) DNA undetectability, low hepatitis B surface antigen ( HBsAg) titre (<250 IU/mL), HBsAg loss, and hepatitis B envelope antigen loss were compared. RESULTS: During interferon treatment, 69 of 270 (25.6%) participants with normal thyroid function at baseline developed thyroid dysfunction, whereas 11 of 72 (15.3%) with thyroid dysfunction at baseline regained normal thyroid function. The thyroid dysfunction group had significantly higher prevalences of low HBsAg titre (29.8% vs. 18.9%) and HBV DNA undetectability (66.0% vs. 40.3%). Multivariate logistic regression analysis showed that thyroid dysfunction was associated with HBsAg loss (odds ratio 4.945, 95% confidence interval 1.325-18.462). CONCLUSIONS: These results suggest that thyroid dysfunction is not an absolute contraindication, but is associated with HBsAg loss, in patients with CHB undergoing α- interferon treatment.
|
Authors | Wenfan Luo, Shuai Wu, Hongjie Chen, Yin Wu, Jie Peng |
Journal | The Journal of international medical research
(J Int Med Res)
Vol. 49
Issue 6
Pg. 3000605211025139
(Jun 2021)
ISSN: 1473-2300 [Electronic] England |
PMID | 34182813
(Publication Type: Journal Article)
|
Chemical References |
- Antiviral Agents
- DNA, Viral
- Hepatitis B Surface Antigens
- Hepatitis B e Antigens
- Interferon-alpha
|
Topics |
- Adult
- Antiviral Agents
(therapeutic use)
- DNA, Viral
(genetics)
- Hepatitis B Surface Antigens
- Hepatitis B e Antigens
- Hepatitis B virus
(genetics)
- Hepatitis B, Chronic
(drug therapy)
- Humans
- Interferon-alpha
(therapeutic use)
- Retrospective Studies
- Thyroid Gland
- Treatment Outcome
|